Business Wire

NY-MEDIDATA

Share
Medidata Announces Rapid Expansion of its Sensor Cloud Network with the Addition of 10 Health Technology Innovators

Medidata , a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network . AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carnegie Mellon University, University of Rochester, and University of Vermont are now part of the first cross-sector collaboration focused on solving the challenges related to sensor integrations, standardization of sensor data, and the development of novel digital biomarkers and algorithms. These will help to create new digital endpoints that could translate into more effective treatments and better healthcare for patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005239/en/

The Sensor Cloud Network, which includes contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academic institutions, creates opportunities for data scientists to refine, test, and deliver physiological algorithms with clinical meaning at scale. Examples include refined motion parameters like gait, cardiovascular metrics, metabolic insights, and clinical-grade speech analytics.

“As the use of sensors in clinical trials is predicted to reach 50% by 20251 , we are focused on making Medidata Sensor Cloud the industry standard for collecting and analyzing medical-grade sensor data,” said Ben Schlatka, vice president, Digital Biomarker Solutions at Medidata. “We are excited to work with a diverse group of partners to help shape the future of patient data collection and analysis, and make Sensor Cloud the platform of choice for developing new digital biomarkers across a wide variety of therapeutic areas.”

Comments from the newest Sensor Cloud Network partners:

AliveCor is pleased to join the Medidata Sensor Cloud Network to help facilitate and expand access to clinical trials for a range of serious conditions. Medidata and AliveCor are democratizing clinical research by providing a reliable way to remotely capture and share important heart health data,” said Aman Bhatti, M.D., senior vice president, Global Biopharma, AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology.

"Aural Analytics is thrilled to partner with an industry leader like Medidata. The inclusion of our technology in Medidata’s innovative platform will greatly enhance its capacity for speech collection and analysis," said Judy Smythe, CEO of Aural Analytics, the industry’s leading neuroscience company harnessing the clinical utility of speech across age ranges and around the world.

“We eagerly look forward to collaborating with Medidata and its partners, as we jointly support and advance the decentralized clinical trial (DCT) process with AI-powered remote patient monitoring technology to better aggregate patient data,” said Arik Ben Ishay, CEO of Biobeat , a medtech company with unique health-AI capabilities in the patient monitoring space.

Blue Spark is excited to become one of the first members of Medidata Sensor Cloud Network. The integration of our TempTraq wearable, wireless continuous temperature monitoring platform gives researchers access to real-time continuous human body temperature data, fed right into the Sensor Cloud Network. TempTraq has been clinically shown to detect fevers up to 18 hours earlier than the standard of care,” said John Gannon, president and CEO of Blue Spark Technologies, Inc., an innovator in wearable, medical device solutions.

“We are very pleased to partner with Medidata’s Sensor Cloud team in making it easier for Life Science organizations to execute global clinical trials, using Glooko’s Connected Research platform. This will benefit researchers in collecting digital endpoints while providing patients with a better trial experience, which will ultimately result in more efficient development of new and novel therapeutics for all disease states,” said Komathi Stem, Chief Operating Officer of Glooko , a digital health company that uses AI/ML algorithms to deliver precision engagement, transform care, and accelerate clinical research.

"We are thrilled to announce this unique partnership with the Medidata Sensor Cloud Network as both of our companies believe that moving clinical research to the home with decentralized data collection will improve the quality of the industry, translating to overall improvements in treatments," said Clint McClellan, CEO, Indie Health , which makes decentralized clinical trials and remote patient monitoring easy, affordable, scalable, and reliable.

“We are leveraging the tools and technology available in the Medidata Sensor Cloud Network to advance and accelerate our work in the development of fall risk detection algorithms in the Multiple Sclerosis population, a disease that affects 2.3M patients worldwide, 50% of whom will experience a fall that negatively impacts their quality of life,” said Dr. Ryan McGinnis, Head of the MSense group at the University of Vermont . “The Sensor Cloud Network is allowing us to explore the combination of patient reported outcomes and medical-grade wearables data in remote settings at scale to better understand this problem and to develop a digital intervention.”

To learn more about the Sensor Cloud Network, please visit here .

Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

  1. Y. Jansen and G. Thornton, “Wearables & Big Data In Clinical Trials — Where Do We Stand?,” Clinical Leader, February 2020. https://www.clinicalleader.com/doc/wearables-big-data-in-clinical-trials-where-do-we-stand-0001 .

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata .

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com .

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye